Literature DB >> 29380230

Thyroid Hormone Promotes β-Catenin Activation and Cell Proliferation in Colorectal Cancer.

Yee-Shin Lee1, Yu-Tang Chin2,3, Ya-Jung Shih2,3, André Wendindondé Nana1, Yi-Ru Chen2,3, Han-Chung Wu4, Yu-Chen S H Yang5, Hung-Yun Lin6,7,8, Paul J Davis9,10.   

Abstract

Thyroid hormone status has long been implicated in cancer development. Here we investigated the role of thyroxine (T4) in colorectal cancer cell lines HCT 116 (APC wild type) and HT-29 (APC mutant), as well as the primary cultures of cancer cells derived from patients. Cell proliferation was evaluated with standard assay and proliferation marker expression. β-Catenin activation was examined according to nuclear β-catenin accumulation and β-catenin target gene expression. The results showed that T4 increased colorectal cancer cell proliferation while cell number and viability were elevated by T4 in both established cell lines and primary cells. Moreover, the transcriptions of proliferative genes PCNA, CCND1, and c-Myc were enhanced by T4 in the primary cells. T4 induced nuclear β-catenin accumulation, as well as high cyclin D1 and c-Myc levels compared to the untreated cells. In addition, the β-catenin-directed transactivation of CCND1 and c-Myc promoters was also upregulated by T4. CTNNB1 transcription was raised by T4 in HCT 116, but not in HT-29, while the boosted β-catenin levels were observed in both. Lastly, the T4-mediated gene expression could be averted by the knockdown of β-catenin. These results suggested that T4 promotes β-catenin activation and cell proliferation in colorectal cancer, indicating that an applicable therapeutic strategy should be considered.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29380230     DOI: 10.1007/s12672-018-0324-y

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  19 in total

1.  β-Catenin regulates deiodinase levels and thyroid hormone signaling in colon cancer cells.

Authors:  Monica Dentice; Cristina Luongo; Raffaele Ambrosio; Annarita Sibilio; Antonella Casillo; Antonino Iaccarino; Giancarlo Troncone; Gianfranco Fenzi; P Reed Larsen; Domenico Salvatore
Journal:  Gastroenterology       Date:  2012-07-03       Impact factor: 22.682

2.  Chromatin immunoprecipitation (ChIP).

Authors:  Michael F Carey; Craig L Peterson; Stephen T Smale
Journal:  Cold Spring Harb Protoc       Date:  2009-09

3.  Thyroid dysfunction, thyroid hormone replacement and colorectal cancer risk.

Authors:  Ben Boursi; Kevin Haynes; Ronac Mamtani; Yu-Xiao Yang
Journal:  J Natl Cancer Inst       Date:  2015-04-08       Impact factor: 13.506

4.  Enhancement by thyroxine of experimental carcinogenesis induced in rat colon by azoxymethane.

Authors:  H Iishi; M Tatsuta; M Baba; S Okuda; H Taniguchi
Journal:  Int J Cancer       Date:  1992-04-01       Impact factor: 7.396

5.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

Review 6.  Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective.

Authors:  Lars C Moeller; Dagmar Führer
Journal:  Endocr Relat Cancer       Date:  2013-03-22       Impact factor: 5.678

7.  Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.

Authors:  Oriol Arqués; Irene Chicote; Isabel Puig; Stephan P Tenbaum; Guillem Argilés; Rodrigo Dienstmann; Natalia Fernández; Ginevra Caratù; Judit Matito; Daniel Silberschmidt; Jordi Rodon; Stefania Landolfi; Aleix Prat; Eloy Espín; Ramón Charco; Paolo Nuciforo; Ana Vivancos; Wenlin Shao; Josep Tabernero; Héctor G Palmer
Journal:  Clin Cancer Res       Date:  2015-07-29       Impact factor: 12.531

8.  Thyroid function and cancer risk: a prospective population study.

Authors:  Alf Inge Hellevik; Bjørn Olav Asvold; Trine Bjøro; Pål R Romundstad; Tom Ivar L Nilsen; Lars J Vatten
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01-20       Impact factor: 4.254

9.  Beta-catenin/Tcf-1-mediated transactivation of cyclin D1 promoter is negatively regulated by thyroid hormone.

Authors:  Hiroko Natsume; Shigekazu Sasaki; Masatoshi Kitagawa; Yumiko Kashiwabara; Akio Matsushita; Keiko Nakano; Kozo Nishiyama; Koji Nagayama; Hiroko Misawa; Hiroko Masuda; Hirotoshi Nakamura
Journal:  Biochem Biophys Res Commun       Date:  2003-09-19       Impact factor: 3.575

10.  β-catenin overexpression in the nucleus predicts progress disease and unfavourable survival in colorectal cancer: a meta-analysis.

Authors:  Zhigang Chen; Xin He; Minyue Jia; Yang Liu; Dihong Qu; Dang Wu; Pin Wu; Chao Ni; Zhigang Zhang; Jun Ye; Jinghong Xu; Jian Huang
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

View more
  13 in total

Review 1.  Thyroid hormone signaling in the intestinal stem cells and their niche.

Authors:  Maria Virginia Giolito; Michelina Plateroti
Journal:  Cell Mol Life Sci       Date:  2022-08-10       Impact factor: 9.207

Review 2.  Platelet ATP, Thyroid Hormone Receptor on Integrin αvβ3 and Cancer Metastasis.

Authors:  Paul J Davis; Shaker A Mousa; Geraldine P Schechter; Hung-Yun Lin
Journal:  Horm Cancer       Date:  2019-12-14       Impact factor: 3.869

3.  Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Anne R Cappola; Francesco S Celi; Eric Fliers; Heike Heuer; Elizabeth A McAninch; Lars C Moeller; Birte Nygaard; Anna M Sawka; Torquil Watt; Colin M Dayan
Journal:  Eur Thyroid J       Date:  2021-02-16

Review 4.  Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Anne R Cappola; Francesco S Celi; Eric Fliers; Heike Heuer; Elizabeth A McAninch; Lars C Moeller; Birte Nygaard; Anna M Sawka; Torquil Watt; Colin M Dayan
Journal:  Thyroid       Date:  2021-02       Impact factor: 6.568

Review 5.  Actions of L-thyroxine (T4) and Tetraiodothyroacetic Acid (Tetrac) on Gene Expression in Thyroid Cancer Cells.

Authors:  Paul J Davis; Hung-Yun Lin; Aleck Hercbergs; Shaker A Mousa
Journal:  Genes (Basel)       Date:  2020-07-07       Impact factor: 4.096

6.  Tetrac and NDAT Induce Anti-proliferation via Integrin αvβ3 in Colorectal Cancers With Different K-RAS Status.

Authors:  Yu-Tang Chin; Zong-Rong He; Chi-Long Chen; Hsiao-Ching Chu; Yih Ho; Po-Yu Su; Yu-Chen S H Yang; Kuan Wang; Ya-Jung Shih; Yi-Ru Chen; Jens Z Pedersen; Sandra Incerpi; André Wendindondé Nana; Heng-Yuan Tang; Hung-Yun Lin; Shaker A Mousa; Paul J Davis; Jacqueline Whang-Peng
Journal:  Front Endocrinol (Lausanne)       Date:  2019-03-12       Impact factor: 5.555

7.  Association Between Thyroid Disorders and Colorectal Cancer Risk in Adult Patients in Taiwan.

Authors:  Abby L'Heureux; Daniel R Wieland; Chien-Huan Weng; Yi-Huei Chen; Ching-Heng Lin; Tseng-Hsi Lin; Chien-Hsiang Weng
Journal:  JAMA Netw Open       Date:  2019-05-03

Review 8.  Herbal Medicines Attenuate PD-L1 Expression to Induce Anti-Proliferation in Obesity-Related Cancers.

Authors:  Yu-Chen S H Yang; Zi-Lin Li; Ya-Jung Shih; James A Bennett; Jaqueline Whang-Peng; Hung-Yun Lin; Paul J Davis; Kuan Wang
Journal:  Nutrients       Date:  2019-12-05       Impact factor: 5.717

9.  NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.

Authors:  Tung-Yung Huang; Tung-Cheng Chang; Yu-Tang Chin; Yi-Shin Pan; Wong-Jin Chang; Feng-Cheng Liu; Ema Dwi Hastuti; Shih-Jiuan Chiu; Shwu-Huey Wang; Chun A Changou; Zi-Lin Li; Yi-Ru Chen; Hung-Ru Chu; Ya-Jung Shih; R Holland Cheng; Alexander Wu; Hung-Yun Lin; Kuan Wang; Jacqueline Whang-Peng; Shaker A Mousa; Paul J Davis
Journal:  Cells       Date:  2020-08-03       Impact factor: 6.600

10.  Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management.

Authors:  Marwa S Hamza; Shaker A Mousa
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.